21,126 Shares in Zenas BioPharma, Inc. $ZBIO Bought by Quantinno Capital Management LP

Quantinno Capital Management LP acquired a new stake in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 21,126 shares of the company’s stock, valued at approximately $413,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Zenas BioPharma by 25.0% in the 4th quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company’s stock valued at $52,761,000 after buying an additional 290,307 shares in the last quarter. NEXTBio Capital Management LP purchased a new position in shares of Zenas BioPharma in the 4th quarter worth approximately $11,691,000. EcoR1 Capital LLC bought a new position in shares of Zenas BioPharma during the 4th quarter worth approximately $28,667,000. Polar Capital Holdings Plc bought a new position in shares of Zenas BioPharma during the 4th quarter worth approximately $38,402,000. Finally, SEB Asset Management AB purchased a new stake in Zenas BioPharma during the first quarter valued at approximately $3,203,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ZBIO. Citigroup reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Wedbush reissued an “outperform” rating and issued a $45.00 price objective on shares of Zenas BioPharma in a research report on Friday, August 14th. Wall Street Zen upgraded Zenas BioPharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. HC Wainwright reaffirmed a “buy” rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Finally, Weiss Ratings lowered Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 9th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Zenas BioPharma has a consensus rating of “Moderate Buy” and an average target price of $45.71.

Zenas BioPharma Stock Up 2.1%

NASDAQ:ZBIO opened at $32.29 on Friday. The company has a market cap of $2.10 billion, a PE ratio of -3.59 and a beta of -1.03. Zenas BioPharma, Inc. has a twelve month low of $13.50 and a twelve month high of $44.60. The company has a current ratio of 9.93, a quick ratio of 9.93 and a debt-to-equity ratio of 1.57. The company’s 50 day moving average is $28.27 and its two-hundred day moving average is $23.78.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.65). The business had revenue of $1.00 million for the quarter, compared to analyst estimates of $15.00 million. Analysts anticipate that Zenas BioPharma, Inc. will post -5.81 EPS for the current year.

Zenas BioPharma Profile

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.